Search clinical trials for: JNJ-54452840

Total 867 results

Janssen Research & Development, LLC

Recruiting

A Study of JNJ-79032421 Targeting Mesothelin for Advanced Stage Solid Tumors

Advanced Stage Solid Tumors

Spain
Janssen Research & Development, LLC

Active, not recruiting

A Study of JNJ-70218902 in Participants With Advanced Stage Solid Tumors

Neoplasms

Canada, Israel, Spain
Janssen Research & Development, LLC

Completed

A Study of JNJ-80038114 in Participants With Advanced Stage Prostate Cancer

Prostatic Neoplasms

United States, United Kingdom
Janssen Research & Development, LLC

Completed

A Study of JNJ-68284528, a Chimeric Antigen Receptor T Cell (CAR-T) Therapy Directed Against B-Cell Maturation Antigen (BCMA) in Participants With Relapsed or Refractory Multiple Myeloma (CARTITUDE-1)

Multiple Myeloma

United States, Japan
Janssen Research & Development, LLC

Completed

A Study of JNJ-63898081 in Participants With Advanced Stage Solid Tumors

Neoplasms

United States, Canada
Janssen Research & Development, LLC

Completed

A Study to Compare Two Different Subcutaneously-administered JNJ-64304500 Formulations in Healthy Participants

Healthy

United States
Janssen Research & Development, LLC

Completed

A Study of JNJ-64565111 After Single Subcutaneous Administration at Different Injection Sites in Otherwise Healthy Overweight/Obese Adult Participants and a Study of JNJ-6456511 in Otherwise Healthy Obese Adult Participants After Multiple Dose

Obesity

United States
Johnson & Johnson Pharmaceutical Research & Development...

Completed

A Research Study of JNJ-26854165 to Determine the Safety and Dose in Patients With Advanced Stage or Refractory Solid Tumors.

Neoplasms
Johnson & Johnson Pharmaceutical Research & Development...

Completed

A Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of JNJ-38431055 in Healthy Male Volunteers

Diabetes Mellitus, Type 2
Janssen Research & Development, LLC

Terminated

A Study of Safety, Pharmacokinetics, Pharmacodynamics of JNJ-61610588 in Participants With Advanced Cancer

Advanced Cancer

United States
Janssen Research & Development, LLC
City of Hope Medical Center

Recruiting

A Study of JNJ-90014496 in Participants With Relapsed or Refractory B-Cell Non-Hodgkin Lymphoma

Relapsed or Refractory B Cell Non-Hodgkin Lymphoma

United States, Australia
Janssen Research & Development, LLC

Active, not recruiting

A Study of JNJ-64264681 in Participants With Non-Hodgkin Lymphoma and Chronic Lymphocytic Leukemia

Lymphoma, Non-Hodgkin | Leukemia, Lymphocytic, Chronic, B-Cell

United States, Taiwan, Poland, United Kingdom, Georgia, Ukraine, Moldova, Republic of
Janssen Research & Development, LLC

Active, not recruiting

A Long-term Extension Study of JNJ-77242113 in Participants With Moderate-to-Severe Plaque Psoriasis (FRONTIER 2)

Plaque Psoriasis

United States, Korea, Republic of, Germany, France, Taiwan, Japan, Spain, United Kingdom, Poland, Canada
Janssen Research & Development, LLC

Completed

A Study of JNJ-64281802 in Healthy Adult Participants

Healthy

Netherlands
Janssen Research & Development, LLC

Completed

Dose Escalation Study of JNJ-63709178, a Humanized CD123 x CD3 DuoBody in Participants With Relapsed or Refractory Acute Myeloid Leukemia (AML)

Leukemia, Myeloid, Acute

United States, Spain
Janssen Research & Development, LLC

Completed

A Study of JNJ-73763989 in Healthy Chinese Adult Participants

Healthy

China
Janssen Vaccines & Prevention B.V.

Completed

A Study to Evaluate the Safety, Tolerability and Immunogenicity of Two Vaccinations of Ad26.RSV.preF One Year Apart in Adults Aged 60 Years and Older in Stable Health

Healthy

United States
Janssen Pharmaceutical K.K.

Completed

A Study to Evaluate the Safety and Immunogenicity of Different Doses of ExPEC4V (JNJ-63871860) in Healthy Japanese Adult Participants

Healthy

Japan
Johnson & Johnson Pharmaceutical Research & Development...
Janssen Pharmaceutica N.V., Belgium

Completed

A Safety and Dose-finding Study of JNJ-26481585 for Patients With Advanced Solid Malignancies and Lymphoma.

Neoplasms | Lymphoma

United Kingdom
Johnson & Johnson Pharmaceutical Research & Development...

Completed

A Study to Evaluate Pharmacokinetics, Safety and Tolerability After a Single Dose Administration of of JNJ-31001074 in Children (6-11 Years) With Attention Deficit Hyperactivity Disorder (ADHD)

Attention Deficit Hyperactivity Disorder | Attention Deficit Disorders With Hyperactivity
Johnson & Johnson Pharmaceutical Research & Development...

Completed

A First-in-Human Study of JNJ-28431754 in Healthy Male Volunteers

Healthy
Janssen Research & Development, LLC

Recruiting

A Study of JNJ-75276617 in Participants With Acute Leukemia

Acute Myeloid Leukemia | Acute Lymphoblastic Leukemia | Acute Leukemias

United States, United Kingdom, France, Spain, Australia
Janssen Research & Development, LLC

Active, not recruiting

A Study of JNJ-67856633 in Participants With Non-Hodgkin's Lymphoma (NHL) and Chronic Lymphocytic Leukemia (CLL)

Lymphoma, Non-Hodgkin | Leukemia, Lymphocytic, Chronic, B-Cell

United States, Korea, Republic of, Israel, Japan, Germany, Spain, Australia, China, France, United Kingdom, Greece, Italy
Janssen Research & Development, LLC

Completed

A Study of JNJ-63733657 in Healthy Chinese Participants

Healthy

China
Janssen Research & Development, LLC

Completed

A Study of JNJ-73763989 in Adult Participants With Renal Impairment

Renal Impairment

Germany
Janssen Pharmaceutica N.V., Belgium

Terminated

A Study to Evaluate the Effect of Renal Impairment on JNJ-64417184 and Its Two Minor Metabolites JNJ-68294291 and JNJ-65201526 in Adult Participants

Renal Impairment

Germany
Janssen Research & Development, LLC

Completed

A Study in Healthy Volunteers to Assess the Effect of Different Types of Food on a Single-dose of JNJ-64417184 Administered as Tablets

Healthy

Netherlands
Janssen Research & Development, LLC

Completed

A Study to Evaluate the Pharmacokinetics of JNJ-38518168 in Patients With Mild and Moderate Hepatic Impairment Compared With Patients With Normal Hepatic Function

Hepatic Impairment

United States
Johnson & Johnson Pharmaceutical Research & Development...
Ortho Biotech, Inc.

Terminated

A Safety and Dose-finding Study of JNJ-38877605 in Patients With Advanced or Refractory Solid Tumors.

Neoplasms
Janssen Research & Development, LLC

Completed

A Study to Evaluate the Bioavailability and Food Effect of JNJ-39439335 in Healthy Adult Male Volunteers

Healthy

United States
Johnson & Johnson Pharmaceutical Research & Development...

Completed

A Study to Evaluate Pharmacokinetics, Safety and Tolerability After a Single Dose Administration of JNJ-31001074 in Pediatric Patients (12-17 Years) With Attention Deficit Hyperactivity Disorder (ADHD)

Attention Deficit Hyperactivity Disorder | Attention Deficit Disorders With Hyperactivity
Janssen Research & Development, LLC

Completed

A Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of JNJ-42721458 in Healthy Male Participants

Healthy

Belgium
Janssen Research & Development, LLC

Completed

A Study to Investigate the Absorption, Metabolism, and Excretion of JNJ-38518168 After a Single Oral Dose in Healthy Male Participants.

Healthy

Belgium
Janssen Sciences Ireland UC

Completed

A Study to Investigate Safety, Tolerability, and Pharmacokinetics of JNJ 53718678 in Healthy Japanese Adult Participants

Healthy

United Kingdom
Janssen Research & Development, LLC

Completed

A Study of JNJ-42847922 (Seltorexant) in Healthy Participants

Healthy

Netherlands
Janssen Sciences Ireland UC

No longer available

Pre-Approval Access to JNJ-53718678 for the Treatment of Respiratory Syncytial Virus (RSV) Infection in (a) Immunocompromised Adult and Pediatric Participants

Respiratory Syncytial Virus
Janssen Research & Development, LLC

Completed

A Study of Seltorexant in Healthy Participants

Healthy

United States
Janssen Research & Development, LLC

Completed

A Study to Investigate the Antidepressant Mechanism-of-action of JNJ-42847922 in Participants With Major Depressive Disorder

Depressive Disorder, Major

Belgium, United Kingdom, Germany, United States, Netherlands
Johnson & Johnson Pharmaceutical Research & Development...

Terminated

An Efficacy and Safety Study of JNJ-26113100 in the Treatment of Adult Atopic Dermatitis

Atopic Dermatitis

United States
Janssen Research & Development, LLC

Not yet recruiting

A Study Comparing Pre- and Post-Change Teclistamab in Participants With Relapsed or Refractory Multiple Myeloma (MajesTEC-10)

Relapsed or Refractory Multiple Myeloma
Janssen Research & Development, LLC

Recruiting

A Study of JNJ-77242113 in Participants With Moderately to Severely Active Ulcerative Colitis (ANTHEM-UC)

Colitis, Ulcerative

Korea, Republic of, Canada, United States, Australia, Czechia, Malaysia, Germany, Turkey, Japan, Belgium, Hungary, Italy, Spain, China, Poland, United Kingdom, Brazil, France, Argentina, Romania, India
Janssen Research & Development, LLC

Recruiting

A Study of JNJ-64281802 for the Prevention of Dengue Infection

Dengue

Mexico, Malaysia, Brazil, Colombia, Puerto Rico, Panama, Peru, Philippines, Thailand
Janssen Research & Development, LLC

Recruiting

A Study of Apalutamide in Participants With Severe Hepatic Impairment Compared With Participants With Normal Hepatic Function

Hepatic Impairment

United States
University of Oxford
Janssen Pharmaceutica

Terminated

MIcroglial Colony Stimulating Factor-1 Receptor (CSF1R) in Alzheimer's Disease (MICAD)

Alzheimer Disease | Mild Cognitive Impairment

United Kingdom
Janssen Research & Development, LLC

No longer available

Pre-Approval Access Single Patient Request for Talquetamab in Relapsed or Refractory Multiple Myeloma

Relapsed or Refractory Multiple Myeloma

Belgium, Iceland, Portugal, Slovenia
Janssen Research & Development, LLC

Approved for marketing

Pre-Approval Access Program for Talquetamab in Relapsed or Refractory Multiple Myeloma

Relapsed or Refractory Multiple Myeloma

Brazil, Germany, Italy, Netherlands, Romania, Switzerland, United Kingdom
Janssen Research & Development, LLC

Completed

A Single and Multiple Ascending Dose Study of Subcutaneously Administered JNJ-75220795

Fatty Liver Disease

United States
Janssen Research & Development, LLC

Terminated

Study to Assess Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of JNJ-64565111 in Type 2 Diabetes Mellitus (T2DM)

Diabetes Mellitus, Type 2

Germany
Janssen Research & Development, LLC

Completed

A Study of JNJ-67484703 in Participants With Active Rheumatoid Arthritis

Rheumatoid Arthritis

Spain, United States, Hungary, Georgia, Moldova, Republic of, Ukraine
Janssen Research & Development, LLC

Completed

A Study of JNJ-64251330 in Participants With Familial Adenomatous Polyposis

Adenomatous Polyposis Coli

United States, Germany, Korea, Republic of, France, Netherlands, Spain, Puerto Rico

Search clinical trials for: JNJ-54452840

Sponsors and Collaborators

Medical Conditions

Drug Interventions

CROs by country

CROs in Mozambique

Conditions

Rare Diseases

Drug Interventions

Dietary Supplements

Sponsor/Collaborators

Locations